貴州百靈(002424.SZ):與遼寧立達糖尿病中醫醫院簽訂技術開發(合作)合同
格隆匯3月28日丨貴州百靈(002424.SZ)公佈,公司(“乙方”)於近日與遼寧立達糖尿病中醫醫院(“甲方”)簽訂《技術開發(合作)合同》。雙方擬共同參與醫療機構製劑“糖寧通絡片”項目的研究和開發,本着風險共擔,利益雙贏的原則,雙方經過平等協商,在真實、充分地表達各自意願的基礎上,根據《中華人民共和國民法典》的規定,達成合同,並由雙方共同恪守。
公司的“糖寧通絡片”將由遼寧立達糖尿病中醫醫院作為主體向遼寧省藥品監督管理局申請《遼寧省醫療機構製劑臨牀研究批件》和《遼寧省醫療機構製劑註冊批件》,存在不能通過相關審批的可能性風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.